ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Development of a point-of-care test for the simultaneous detection of respiratory syncytial virus and IL-33 as a disease biomarker in children.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe human respiratory syncytial virus (hRSV) is a leading cause of acute respiratory disease in children under 5 years of age. hRSV infection is associated with significant morbidity and mortality and represents a substantial economic burden for public health systems worldwide. Early and accurate diagnosis is critical for effective patient management, but current diagnostic tools, such as RT-qPCR, require specialized equipment and personnel. Further, currently available methods do not provide information regarding the prognosis of the disease caused by hRSV. Given this scenario, we aimed at generating and pre-validating a new rapid diagnosis test based on an immunochromatographic strip (ICS) to be used as a point-of-care (POC) test capable of simultaneously detecting the phosphoprotein P of hRSV (P-hRSV) and a biomarker of disease severity, interleukin-33 (IL-33) in nasal swabs.
methodsMonoclonal antibodies against P-hRSV and IL-33 were produced and incorporated into an ICS. The 20-min rapid diagnostic test was evaluated and validated with recombinant proteins, virus-infected cells, viral dilutions, and hRSV-positive and negative clinical samples. Sensitivity and specificity were assessed.
resultsThe ICS detected 103 pg of P-hRSV and as low as 187 PFUs of hRSV. Regarding recombinant IL-33, the ICS detected as low as 780 pg. The test strip exhibited high specificity, distinguishing hRSV from other respiratory viruses, including influenza and human metapneumovirus. Additionally, IL-33 was detected in some non-RSV infections.
conclusionsThe data obtained supports the feasibility of a combined rapid test detecting simultaneously hRSV and IL-33, which can be useful as a POC test for screening severe cases of hRSV in primary care settings and emergency rooms.
Indexed as
Identifiers
40148664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.